Abstract OT3-06-05: A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer 'PantHER'

MLA

K. Egan, et al. “Abstract OT3-06-05: A Phase Ib/II Trial of CoPANlisib in Combination with Tratuzumab in Pretreated Recurrent or Metastatic HER2-Positive Breast Cancer ‘PantHER.’” Cancer Research, vol. 78, Feb. 2018, pp. OT3-06. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........a1835a688421524ea4b5aef17856ae6f&authtype=sso&custid=ns315887.

APA

K. Egan, M Given, Liam Grogan, Andres Hernando, Sinead Toomey, Oscar S. Breathnach, M. Keane, K Bulger, Niamh M. Keegan, Giuseppe Gullo, Patrick G. Morris, CM Kelly, Ausra Teiserskiene, Janice M. Walshe, J Crown, John James Kennedy, J Kerr, & Bryan T. Hennessy. (2018). Abstract OT3-06-05: A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER.” Cancer Research, 78, OT3-06.

Chicago

K. Egan, M Given, Liam Grogan, Andres Hernando, Sinead Toomey, Oscar S. Breathnach, M. Keane, et al. 2018. “Abstract OT3-06-05: A Phase Ib/II Trial of CoPANlisib in Combination with Tratuzumab in Pretreated Recurrent or Metastatic HER2-Positive Breast Cancer ‘PantHER.’” Cancer Research 78 (February): OT3-06. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........a1835a688421524ea4b5aef17856ae6f&authtype=sso&custid=ns315887.